Giant prolactinomas in women

Area of Science:

• Endocrinology
• Neuro-oncology
• Reproductive Medicine

Background:

• Giant prolactinomas (pituitary tumors >4 cm with prolactin >1000 μg/l) are rare, particularly in women.
• Understanding their distinct clinical features is crucial for timely diagnosis and effective management.

Observation:

• A multicenter retrospective case series and literature review identified 34 female patients with giant prolactinomas.
• Women were diagnosed later (median age 44) than men (median age 35), with a bimodal age distribution peaking in the third and fifth decades.
• Amenorrhea was universal, and diagnosis was often delayed by a median of 9 years, primarily due to mass effect symptoms.

Findings:

• Giant prolactinomas in women are rare, with a female:male ratio of 1:9.
• A significant proportion of female patients (15/34) had extremely high prolactin levels (>10,000 μg/l).
• Treatment with cabergoline showed limited efficacy, with standard doses normalizing prolactin in only 4/18 patients, and 7/18 exhibiting resistance to higher doses.

Implications:

• The rarity and late diagnosis in women highlight the need for increased awareness of giant prolactinomas.
• Resistance to dopamine agonists suggests that alternative or adjuvant therapies may be necessary for effective management.
• The bimodal age distribution warrants further investigation into potential underlying factors contributing to late-onset disease.